Table 1.
High-IgD CRS Patients (n=12) | Low-IgD CRS patients (n=48) | P-value | |
---|---|---|---|
IgD (ng/mg total protein) in UT, mean (range) | 1307 (568.7–4875) | 134.1 (5.216–479.8) | <.0001 |
Prevalence of CRSsNP, % (Ratio of CRSsNP:CRSwNP) | 75.0% (9:3) | 43.7% (21:27) | .05 |
Purulent rhinorrhea on endoscopy | 0% | 12.5% | 0.33 |
| |||
Medication use (< 4weeks of sinus surgery), % | |||
Antibiotics | 33.3% | 6.3% | .01 |
Nasal corticosteroids | 20.0% | 17.2% | .84 |
Oral corticosteroids | 20.0% | 33.3% | .42 |
| |||
Asthma,% | 41.7% | 37.5% | .79 |
Atopy,% | 54.5% | 68.3% | .39 |
ECP (ng/mg total protein), mean (range) | 757.4 (1.53–7682) | 309.9 (14–1694) | .39 |
Lund-Mackay score28, mean (range) | 10.5 (6–16) | 13.0 (3–24) | .09 |
CRS, chronic rhinosinusitis; UT, uncinate tissue; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps; ECP, eosinophil cationic protein
Text in boldface indicates statistically significant differences for that variable between high-IgD CRS patients and low-IgD CRS patients (P < .05).